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Infantile cholestatic diseases can be caused by mutations in a number of genes involved in different hepatocyte
molecular pathways. Whilst some of the essential pathways have a well understood function, such as bile
biosynthesis and transport, the role of the others is not known. Here we report the findings of a clinical,
biochemical and molecular study of a family with three patients affected with a severe infantile cholestatic disease.
A novel homozygous frameshift germline mutation (c.587delG) in the AKR1D1 gene; which encodes the enzyme
Δ 4-3-oxosteroid 5β–reductase that is required for synthesis of primary bile acids and is crucial for establishment of
normal bile flow, was found in all 3 patients. Although the initial bile acid analysis was inconclusive, subsequent
testing confirmed the diagnosis of a bile acid biogenesis disorder. An additional novel homozygous frameshift
mutation (c.3391delC) was detected in SKIV2L in one of the patients. SKIV2L encodes a homologue of a yeast ski2
protein proposed to be involved in RNA processing and mutations in SKIV2L were recently described in patients
with Tricohepatoenteric syndrome (THES). A combination of autozygosity mapping and whole-exome-sequencing
allowed the identification of causal mutations in this family with a complex liver phenotype. Although the initial 2
affected cousins died in the first year of life, accurate diagnosis and management of the youngest patient led to
successful treatment of the liver disease and disease-free survival.
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Background
Neonatal cholestasis affects approximately one in 2,500
births and results from diminished bile flow or secretion.
The aetiology of the neonatal cholestasis is highly
variable and includes infections, inborn errors of meta-
bolism including bile acid synthesis and transport
disorders, and mechanical obstruction (e.g. biliary atresia)
[1]. Early recognition and diagnosis of neonatal cholestasis
is essential to permit effective clinical management. In
recent years new genetic causes of cholestasis have been* Correspondence: n.v.morgan@bham.ac.uk
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reproduction in any medium, provided the ordefined which have led to a greater understanding of the
mechanisms of bile secretion, liver development and
physiology. These include among others, defects in bile
acid synthesis [2], and transport. However, the function of
many genes that are associated with cholestatic diseases is
still poorly understood. Recent advances in gene sequen-
cing technologies have made it possible to determine the
sequence of most genes, and these novel approaches facili-
tate identification of disease causing mutations in patients
with complex phenotypes [3].Case reports
We studied a consanguineous family of Pakistani descent
consisting of three patients who were first cousins
(Figure 1).l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Identification of AKR1D1 and SKIV2L mutations in a multiple-consanguineous family with severe infantile liver disease. The
initial proband investigated is patient 1 (V:4; P1) her cousin (V:7; P2) is patient 2 and affected sibling (V:8; P3). Solid symbols represent affected
individuals. The segregation of the 2 mutations identified are shown. The upper mutation is a homozygous single base G deletion in AKR1D1
leading to a frameshift and premature stop codon (c.587delG; p.Cys196SerfsX11) and lower mutation a single base C deletion in SKIV2L leading to
a frameshift and premature stop codon (c.3391delC;p.Leu1131SerfsX5).
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The proband, (Patient 1, V:4), a female child was born at
full-term by Caesarean section and was well and breast-
fed for one month before switching to standard infant
formula. At nine weeks of age she was investigated for
progressive cholestasis (serum bilirubin 534 μmol/L (0-15
μmol/L), gamma glutamyl transferase (GGT) 131 IU/L
(25-70 IU/L), alanine transaminase (ALT) 1769 IU/L
(5-45 IU/L), aspartate transaminase (AST) 2078 IU/L
(20-60 IU/L)) and persistent hypoglycaemia. She had no
dysmorphic features and no diarrhoea. She was found to
be hyperinsulinaemic and required diazoxide to establish
good glycaemic control. At nine weeks of age she had a
firm liver, which was palpable 3 cm below the costal
margin and no splenomegaly. An abdominal ultrasound
scan, chest x-ray and ocular examination were all entirely
normal. A radioisotope scan of bile secretion (TiBIDA)
identified good uptake of isotope into the liver but no
excretion. Cardiac and ophthalmology investigations were
all normal. Metabolic screen was consistent with a liver
dysfunction but excluded metabolic causes of cholestasis,
such as galactosaemia, tyrosinaemia, cystic fibrosis, amino
and organic acid disorders, glycosylation defects, glycogen
storage diseases, mitochondrial respiratory chain and fatty
acid oxidation defects. The negative ion FAB-MS analysis
(Additional file 1: supplementary methods) of the urine
revealed dominant ions at m/z 448 and 498 that were
consistent with glycine and taurine conjugated dihydroxy-
cholanoic acids, respectively. These ions are consistent in
mass to the normal primary bile acids conjugates of
chenodeoxycholic acid, suggesting that there was no de-
fect in primary bile acid synthesis (Figure 2). Similarly, the
low intensity ions at m/z 464 and m/z 514 indicated the
presence of the corresponding trihydroxy-cholanoic acid
conjugates, which would be consistent with cholic acid
conjugates. There were low intensity ions at m/z 494 and510, which reflected the presence of oxo-monohydroxy-
and oxo-dihydroxy-cholenoic acids (unsaturated bile
acids). In addition, the ions at m/z 471 and m/z 528 were
consistent with the presence of sulfate and glyco-sulfate
conjugates of dihydroxy-cholanoic acids these ions are
typically present in the mass spectra of urine from patients
undergoing ursodeoxycholic acid (UDCA) treatment.
A liver biopsy at 2 months of age showed florid giant-
cell transformation, marked cholestasis and ballooned
hepatocytes. There were numerous areas of extrame-
dullary haematopoesis and mild iron deposition. There
was no mature fibrosis and ductular proliferation was
rarely seen. Electron microscopy showed whorled inclu-
sions and myelin figures as well as large pale inclusions
containing electron dense material the nature of which
was uncertain. She was diagnosed with neonatal hepatitis
due to a possible disorder of bile transport and treated
with ursodeoxycholic acid and supportive nutrition includ-
ing fat-soluble vitamins. Despite this her liver function de-
teriorated (prothrombin time 28 seconds, albumin 21 g/L)
and she developed ascites. She was listed for liver trans-
plantation but died awaiting a suitable organ.
Patient 2
Patient 2 (V:7), a female cousin of patient 1 was born at
term by Caesarean section for symmetrical intrauterine
growth retardation weighing 1770 g (<0.4th centile) and
reduced liquor. She was well at birth but soon developed
hypoglycaemia, which required intravenous infusions of
high concentration (18 mg/kg/min) dextrose solution.
She had a rising conjugated hyperbilirubinaemia from
birth (285 μmol/l at 6 months) with normal GGT
67 μmol/L. Other transaminases were abnormally raised
(ALT 441 IU/L, AST 84 IU/L). Liver biopsy at six
months showed marked cholestasis and hepatocyte
ballooning with giant cell transformation. There was
Figure 2 Mass Spectrometric analysis of Urine. (A) The negative ion fast atom bombardment ionization mass spectrum of the urine from
patient 1. (B) GC-MS analysis of the methyl ester-trimethylsilyl ether derivatives of bile acids in the urine of patient 1 identified with a mutation in
the AKR1D1 gene and undergoing bile acid therapy with ursodeoxycholic acid. The following compounds were identified from their mass spectra
and retention indices: 1. cholesterol; 2. 3a,7a,12a-trihydroxy-5a-cholanoic and 3b-hydroxy-5-cholenoic acids; 3. unknown; 4. unknown; 5. 3a,
6a-dihydroxy-5b-cholanoic; 6. 3a,7b-dihydroxy-5b-cholanoic (UDCA); 7. 3,7-dihydroxy-cholanoic isomer; 8. 3-oxo-7a-hydroxy-4-cholenoic; 9.
oxo-dihydroxy-cholanoic; 10. trihydroxy-cholanoic; 11. impurity; 12; dihydroxy-cholanoic acid; 13. 3-oxo-7a,12a-dihydroxy-4-cholenoic; 14. 1b,3a,
7a-trihydroxy-cholanoic; 15. 3a,6b,7b-trihydroxy-5b-cholanoic; 16. 3a,4b,12a-trihydroxy-cholanoic; i.s. 1. internal standard, coprostanol; i.s. 2 internal
standard, nordeoxycholic acid.
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bridging fibrosis.
Within two weeks of birth she also developed severe
life threatening diarrhoea with watery yellow stool,
requiring parenteral nutrition from four weeks of age to
maintain growth and hydration. At the time of hypo-
glycaemia, growth hormone, cortisol and lactate were
normal. Although a suppressed ketotic response was
found, there was no recorded hyperinsulinism. The stool
investigations showed a predominant chloride loss (102),
with sodium 90 mEq/L, osmolarity 244 mosmol/kg, pH
7.9 and normal faecal elastase. Common causes of
cholestasis were excluded as in patient 1. Bone marrow
examination was normal.
Duodenal biopsies showed subtotal villous atrophy
with an increased number of intraepithelial lymphocytes
and epithelial apoptosis. There were no histological
features suggestive of microvillous inclusion disease,
tufting enteropathy or autoimmune enteropathy. The
serum immunoglobulin levels were low (IgG < 0.01 g/L
(0.3-0.5). Investigation of the patient’s hair identified
trichorrhexis nodosa with low cysteine and high leucine
content, which led to the consideration of THES as the
underlying unifying diagnosis. However, sequencing of the
exons and exon-intron boundaries was negative for
mutations in TTC37.
The liver disease progressed rapidly with serum bilirubin
rising to 389 μmol/L, falling albumin (20 g/L (34-42 g/L),
rising prothrombin time (21 seconds (normal range 10-13seconds) and falling platelets (40 ×109/L (150-400 ×109/L).
Liver transplantation was proposed but the family re-
quested active palliation with death occurred at the age of 9
months.
Molecular Genetic analysis and identification of AKR1D1
novel mutation
As the known causes of cholestatic liver disease were
excluded in this family we hypothesized that all affected
children had a novel autosomal recessively inherited
disorder and undertook genetic linkage studies in
combination with whole exome sequencing on the
genomic DNA of affected patients 1 and 2. Genome-
wide SNP genotyping using the Affymetrix 250 k SNP
microarray and analysis using HomozygosityMapper in
both affected children showed the largest overlap-
ping autozygous regions at chromosome 7 (134,406,000-
159,126,632 bp), chromosome 16 (906,887-11,568,826 bp),
chromosome 20 (55,452,732-59,208,834 bp), chromosome
12 (64,283,014-67,448,660 bp) and chromosome 4
(77,794,236-79,095,407 bp). In addition the exomes of
patients 1 and 2 were sequenced (Additional file 1: supple-
mentary methods) and the alignment of the sequencing
reads revealed that 83% and 76% of the CCDS defined
exome was covered by >20 high quality reads identifying
17,844 and 17,867 variations in patients 1 and 2 re-
spectively. Comparisons with dbSNP build 131, the 1000
Genomes project database and our in-house database
(composed of 40 exomes), identified 7, 6, 1, 1 and 1 novel
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regions respectively. Of these only 3 homozygous
nonsynonymous variants and 1 frameshift variant were
found in both patients. The frameshift was a homozygous
single base G deletion (c.587delG) in exon 6 of AKR1D1
that mapped within the chromosome 7 candidate linkage
region of the family. The variant results in a frameshift at
amino acid 196 leading to a premature stop codon 11
amino acids downstream (p.Cys196SerfsX11). We vali-
dated this variant by Sanger sequencing on genomic
DNA, which segregated with the disease status in all fam-
ily members (Figure 1). AKR1D1 encodes Δ4-3-oxosteroid
5β-reductase, however the initial bile acid analysis in pa-
tient 1 seemed to exclude a bile acid biosynthesis defect.
Successful treatment of the new Patient 3 with cholic acid
A female sibling (Patient 3; V:8) of Patient 2, was born
following a normal pregnancy by Caesarean section at
term with a birth weight of 7 3.4 kg. She developed
neonatal jaundice, which cleared spontaneously and was
reviewed at five weeks of age. DNA from this patient
was screened for the presence of the AKR1D1 mutation
that was identified in the other 2 affected children in this
family and indeed was found to be homozygous for
c.587delG.
A urine sample was obtained from patient 3 and
analyzed by the same method described above. The
negative ion FAB-MS spectrum profile indicated a
marked elevation in urinary bile acid excretion consist-
ent with a severe cholestasis. The profile revealed eleva-
tions in taurine and glycine conjugates of unsaturated
oxo-dihydroxy and oxo-trihydroxy bile acids. Intense
ions at m/z 460 and 510 reflected the presence of high
concentrations of Δ4-3-oxo bile acids that are characte-
ristic of a bile acid synthetic defect involving a deficiency
in the activity of Δ4-3-oxosteroid 5β-reductase enzyme.
The child was initially started on 15 mg/kg/day of Cholic
Acid in three divided doses and the liver function tests
remained normal until an episode of non-compliance
with medication when the following abnormalities were
identified: ALT of 390 IU/L, AST 324 IU/L and GGT
40 IU/L but normal bilirubin of 6 mmol/L. Liver func-
tion became normal again at the age of 5 months after
improved compliance with the medication. The child
was well, asymptomatic for presence of liver disease and
developing normally at the time of the most recent
review aged 12 months.
Identification of an additional SKIV2L mutation in patient 2
The striking clinical THES phenotype in addition to the
liver disease identified in patient 2 and absence of it in her
cousin, who had proven Δ4-3-oxosteroid 5β-reductase de-
ficiency, suggested that additional pathology was present
in patient 2 compared with her sibling (patient 3) andcousin (patient 1). More recently SKIV2L mutations have
been described in THES patients negative for TTC37 mu-
tations [4]. We then scrutinized the whole exome data in
patient 2 and specifically looked for mutations present in
patient 2 which were absent in patient 1. This revealed a
homozygous frameshift mutation in SKIV2L (c.3391delC;
p.Leu1131SerfsX5) in patient 2 which was not present in
her affected sibling and cousin (Figure 1).
Conclusions
We have described three patients from a multiple
consanguineous family with severe liver disease. In
addition, patient 2 had severe diarrhoea requiring paren-
teral nutrition, and other features of THES including
hair amino acid abnormalities which are found in these
patients. As part of the clinical investigations sequencing
of TTC37, mutations in which were known to cause
THES, was undertaken but revealed no abnormalities. A
combination of genome wide linkage scan and whole
exome sequencing was performed to look for other
genetic causes of liver disease in this family. All three of
the patients were found to have a homozygous mutation
in AKR1D1, consistent with a treatable bile acid biosyn-
thesis disorder. Further bile acid analysis and successful
treatment of patient 3 confirmed the initial diagnosis.
Furthermore, patient 2 was found to have an additional
disease causing mutation in SKIV2L, that was only
recently described to cause THES.
Bile acid synthesis disorders can normally be identified
by measurement of bile acids in the urine using liquid
secondary ionization mass spectrometry [2]. However,
the presence of exogenous bile acids, such as ursodeo-
xycholic acid (UDCA), may mask the ability to detect a
bile acid synthetic defect because UDCA and primary
bile acids, being stereoisomers, have the same molecular
weight. The FAB-MS analysis of the urine from patient
1, performed in 2003, revealed very high concentrations
of dihydroxy-bile acid conjugates derived from the
administered UDCA. There was no evidence for sub-
stantial amounts of Δ4-3-oxo bile acids that characterize
a deficiency in Δ4-3-oxosteroid 5β-reductase [5], and the
mass spectrum was not consistent with this bile acid
disorder [2]. More comprehensive GC-MS analysis
performed 8 years later on this original urine sample,
and only after the identification of the mutation in
AKR1D1, showed that Δ4-3-oxo bile acids, while present,
accounted for <2% of the total bile acids in urine, and
the 5α-reduced metabolite, allo-cholic acid also synthe-
sized in patients with Δ4-3-oxosteroid 5β-reductase
deficiency was also found in traces [6], because the urine
was dominated by UDCA and its metabolites (data not
shown). Δ4-3-Oxo bile acids are normal metabolites of
the urine of neonates and are consistently found in cases
of advanced liver disease [7-10]. Cholic or cheno-
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however in our case they were not identified. 5β-
reduced bile acids were identified in the urine of patient
1 which are presumed to be metabolites of UDCA (a 5β-
cholanoic acid) and its metabolites. Thus, the more
comprehensive GC-MS analysis of the urine of patient 1
would support the diagnosis of a Δ4-3-oxosteroid 5β-
reductase deficiency, with the complementary molecular
confirmation of a mutation in AKR1D1 in this patient.
Bile acid synthesis disorders account for approximately
2% of idiopathic forms of liver disease but are important
to diagnose as they can be treated by supplementation of
primary bile acids, which is highlighted by this report.
Indeed the new affected sibling of Patient 2 responded
well to treatment with Cholic acid.
In conclusion we have extended the clinical features of
Δ4-3-oxosteroid 5β-reductase enzyme deficiency as
severe hypoglycaemia has not been previously reported.
We also highlight the importance of performing urinary
bile acid analysis in the absence of UDCA therapy in
combination with genetic analysis. We also expand the
mutational spectrum of SKIV2L and provide the first
report of a combined phenotype of THES and Δ4-3-
oxosteroid 5β-reductase enzyme deficiency. Combining
the technique of whole genome linkage mapping and
whole exome sequencing creates a powerful tool to
elucidate the molecular basis of uncharacterized genetic
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